nodes	percent_of_prediction	percent_of_DWPC	metapath
Imiquimod—CYP1A2—Sorafenib—liver cancer	0.00537	0.543	CbGbCtD
Imiquimod—CYP3A4—Sorafenib—liver cancer	0.00281	0.284	CbGbCtD
Imiquimod—Viral infection—Epirubicin—liver cancer	0.0018	0.00305	CcSEcCtD
Imiquimod—Herpes simplex—Epirubicin—liver cancer	0.00177	0.00299	CcSEcCtD
Imiquimod—Angioedema—Sorafenib—liver cancer	0.00176	0.00298	CcSEcCtD
Imiquimod—Syncope—Sorafenib—liver cancer	0.00173	0.00292	CcSEcCtD
Imiquimod—Ulcer—Epirubicin—liver cancer	0.00172	0.00291	CcSEcCtD
Imiquimod—Cardiovascular disorder—Doxorubicin—liver cancer	0.00171	0.0029	CcSEcCtD
Imiquimod—CYP3A4—Doxorubicin—liver cancer	0.00171	0.173	CbGbCtD
Imiquimod—Bone pain—Epirubicin—liver cancer	0.0017	0.00288	CcSEcCtD
Imiquimod—Loss of consciousness—Sorafenib—liver cancer	0.00169	0.00287	CcSEcCtD
Imiquimod—Cough—Sorafenib—liver cancer	0.00168	0.00284	CcSEcCtD
Imiquimod—Inflammation—Epirubicin—liver cancer	0.00168	0.00284	CcSEcCtD
Imiquimod—Viral infection—Doxorubicin—liver cancer	0.00167	0.00282	CcSEcCtD
Imiquimod—Hypertension—Sorafenib—liver cancer	0.00166	0.00281	CcSEcCtD
Imiquimod—Myalgia—Sorafenib—liver cancer	0.00164	0.00278	CcSEcCtD
Imiquimod—Arthralgia—Sorafenib—liver cancer	0.00164	0.00278	CcSEcCtD
Imiquimod—Herpes simplex—Doxorubicin—liver cancer	0.00164	0.00277	CcSEcCtD
Imiquimod—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00163	0.00276	CcSEcCtD
Imiquimod—Vaginal inflammation—Epirubicin—liver cancer	0.00163	0.00276	CcSEcCtD
Imiquimod—Dry mouth—Sorafenib—liver cancer	0.0016	0.00271	CcSEcCtD
Imiquimod—Ulcer—Doxorubicin—liver cancer	0.00159	0.0027	CcSEcCtD
Imiquimod—Influenza like illness—Epirubicin—liver cancer	0.00158	0.00268	CcSEcCtD
Imiquimod—Bone pain—Doxorubicin—liver cancer	0.00157	0.00266	CcSEcCtD
Imiquimod—Infection—Sorafenib—liver cancer	0.00156	0.00264	CcSEcCtD
Imiquimod—Skin exfoliation—Epirubicin—liver cancer	0.00155	0.00263	CcSEcCtD
Imiquimod—Inflammation—Doxorubicin—liver cancer	0.00155	0.00263	CcSEcCtD
Imiquimod—Shock—Sorafenib—liver cancer	0.00155	0.00262	CcSEcCtD
Imiquimod—Nervous system disorder—Sorafenib—liver cancer	0.00154	0.00261	CcSEcCtD
Imiquimod—Vaginal infection—Epirubicin—liver cancer	0.00154	0.0026	CcSEcCtD
Imiquimod—Skin disorder—Sorafenib—liver cancer	0.00153	0.00258	CcSEcCtD
Imiquimod—Vaginal inflammation—Doxorubicin—liver cancer	0.00151	0.00255	CcSEcCtD
Imiquimod—Anorexia—Sorafenib—liver cancer	0.0015	0.00254	CcSEcCtD
Imiquimod—Influenza like illness—Doxorubicin—liver cancer	0.00146	0.00248	CcSEcCtD
Imiquimod—Pulmonary oedema—Epirubicin—liver cancer	0.00145	0.00245	CcSEcCtD
Imiquimod—Skin exfoliation—Doxorubicin—liver cancer	0.00144	0.00243	CcSEcCtD
Imiquimod—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00143	0.00242	CcSEcCtD
Imiquimod—Vaginal infection—Doxorubicin—liver cancer	0.00142	0.00241	CcSEcCtD
Imiquimod—Dyspnoea—Sorafenib—liver cancer	0.0014	0.00237	CcSEcCtD
Imiquimod—Lymphadenopathy—Epirubicin—liver cancer	0.00139	0.00234	CcSEcCtD
Imiquimod—Dyspepsia—Sorafenib—liver cancer	0.00138	0.00234	CcSEcCtD
Imiquimod—Decreased appetite—Sorafenib—liver cancer	0.00137	0.00231	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Sorafenib—liver cancer	0.00136	0.0023	CcSEcCtD
Imiquimod—Fatigue—Sorafenib—liver cancer	0.00136	0.00229	CcSEcCtD
Imiquimod—Hepatic function abnormal—Epirubicin—liver cancer	0.00135	0.00229	CcSEcCtD
Imiquimod—Pain—Sorafenib—liver cancer	0.00134	0.00228	CcSEcCtD
Imiquimod—Pulmonary oedema—Doxorubicin—liver cancer	0.00134	0.00227	CcSEcCtD
Imiquimod—Eczema—Epirubicin—liver cancer	0.00132	0.00223	CcSEcCtD
Imiquimod—Gastrointestinal pain—Sorafenib—liver cancer	0.00129	0.00218	CcSEcCtD
Imiquimod—Lymphadenopathy—Doxorubicin—liver cancer	0.00128	0.00217	CcSEcCtD
Imiquimod—Dermatitis exfoliative—Epirubicin—liver cancer	0.00125	0.00212	CcSEcCtD
Imiquimod—Hepatic function abnormal—Doxorubicin—liver cancer	0.00125	0.00212	CcSEcCtD
Imiquimod—Urticaria—Sorafenib—liver cancer	0.00125	0.00211	CcSEcCtD
Imiquimod—Abdominal pain—Sorafenib—liver cancer	0.00124	0.0021	CcSEcCtD
Imiquimod—Body temperature increased—Sorafenib—liver cancer	0.00124	0.0021	CcSEcCtD
Imiquimod—Purpura—Epirubicin—liver cancer	0.00123	0.00208	CcSEcCtD
Imiquimod—Eczema—Doxorubicin—liver cancer	0.00122	0.00206	CcSEcCtD
Imiquimod—Cardiac failure—Epirubicin—liver cancer	0.00121	0.00205	CcSEcCtD
Imiquimod—Lethargy—Epirubicin—liver cancer	0.00121	0.00204	CcSEcCtD
Imiquimod—Cerebrovascular accident—Epirubicin—liver cancer	0.00121	0.00204	CcSEcCtD
Imiquimod—Pain in extremity—Epirubicin—liver cancer	0.00118	0.002	CcSEcCtD
Imiquimod—Migraine—Epirubicin—liver cancer	0.00116	0.00197	CcSEcCtD
Imiquimod—Dermatitis exfoliative—Doxorubicin—liver cancer	0.00116	0.00196	CcSEcCtD
Imiquimod—Hypersensitivity—Sorafenib—liver cancer	0.00116	0.00196	CcSEcCtD
Imiquimod—Face oedema—Epirubicin—liver cancer	0.00114	0.00193	CcSEcCtD
Imiquimod—Purpura—Doxorubicin—liver cancer	0.00113	0.00192	CcSEcCtD
Imiquimod—Asthenia—Sorafenib—liver cancer	0.00113	0.00191	CcSEcCtD
Imiquimod—Cardiac failure—Doxorubicin—liver cancer	0.00112	0.0019	CcSEcCtD
Imiquimod—Cerebrovascular accident—Doxorubicin—liver cancer	0.00112	0.00189	CcSEcCtD
Imiquimod—Lethargy—Doxorubicin—liver cancer	0.00112	0.00189	CcSEcCtD
Imiquimod—Pruritus—Sorafenib—liver cancer	0.00111	0.00188	CcSEcCtD
Imiquimod—Pain in extremity—Doxorubicin—liver cancer	0.00109	0.00185	CcSEcCtD
Imiquimod—Migraine—Doxorubicin—liver cancer	0.00108	0.00182	CcSEcCtD
Imiquimod—Diarrhoea—Sorafenib—liver cancer	0.00108	0.00182	CcSEcCtD
Imiquimod—Breast disorder—Epirubicin—liver cancer	0.00107	0.00181	CcSEcCtD
Imiquimod—Face oedema—Doxorubicin—liver cancer	0.00106	0.00179	CcSEcCtD
Imiquimod—Dizziness—Sorafenib—liver cancer	0.00104	0.00176	CcSEcCtD
Imiquimod—Influenza—Epirubicin—liver cancer	0.00102	0.00173	CcSEcCtD
Imiquimod—Vomiting—Sorafenib—liver cancer	0.001	0.00169	CcSEcCtD
Imiquimod—Rash—Sorafenib—liver cancer	0.000991	0.00168	CcSEcCtD
Imiquimod—Dermatitis—Sorafenib—liver cancer	0.00099	0.00168	CcSEcCtD
Imiquimod—Breast disorder—Doxorubicin—liver cancer	0.000988	0.00167	CcSEcCtD
Imiquimod—Headache—Sorafenib—liver cancer	0.000985	0.00167	CcSEcCtD
Imiquimod—Bronchitis—Epirubicin—liver cancer	0.000983	0.00166	CcSEcCtD
Imiquimod—Pancytopenia—Epirubicin—liver cancer	0.00097	0.00164	CcSEcCtD
Imiquimod—Dysuria—Epirubicin—liver cancer	0.000955	0.00162	CcSEcCtD
Imiquimod—Upper respiratory tract infection—Epirubicin—liver cancer	0.00095	0.00161	CcSEcCtD
Imiquimod—Influenza—Doxorubicin—liver cancer	0.000945	0.0016	CcSEcCtD
Imiquimod—Nausea—Sorafenib—liver cancer	0.000934	0.00158	CcSEcCtD
Imiquimod—Photosensitivity reaction—Epirubicin—liver cancer	0.000933	0.00158	CcSEcCtD
Imiquimod—Infestation—Epirubicin—liver cancer	0.000911	0.00154	CcSEcCtD
Imiquimod—Infestation NOS—Epirubicin—liver cancer	0.000911	0.00154	CcSEcCtD
Imiquimod—Bronchitis—Doxorubicin—liver cancer	0.000909	0.00154	CcSEcCtD
Imiquimod—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.000903	0.00153	CcSEcCtD
Imiquimod—Pancytopenia—Doxorubicin—liver cancer	0.000898	0.00152	CcSEcCtD
Imiquimod—Neuropathy peripheral—Epirubicin—liver cancer	0.000893	0.00151	CcSEcCtD
Imiquimod—Conjunctivitis—Epirubicin—liver cancer	0.000886	0.0015	CcSEcCtD
Imiquimod—Urinary tract infection—Epirubicin—liver cancer	0.000886	0.0015	CcSEcCtD
Imiquimod—Dysuria—Doxorubicin—liver cancer	0.000884	0.0015	CcSEcCtD
Imiquimod—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000879	0.00149	CcSEcCtD
Imiquimod—Photosensitivity reaction—Doxorubicin—liver cancer	0.000863	0.00146	CcSEcCtD
Imiquimod—Hepatobiliary disease—Epirubicin—liver cancer	0.000862	0.00146	CcSEcCtD
Imiquimod—Sinusitis—Epirubicin—liver cancer	0.000855	0.00145	CcSEcCtD
Imiquimod—Infestation NOS—Doxorubicin—liver cancer	0.000843	0.00143	CcSEcCtD
Imiquimod—Infestation—Doxorubicin—liver cancer	0.000843	0.00143	CcSEcCtD
Imiquimod—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.000836	0.00141	CcSEcCtD
Imiquimod—Neuropathy peripheral—Doxorubicin—liver cancer	0.000826	0.0014	CcSEcCtD
Imiquimod—Haemoglobin—Epirubicin—liver cancer	0.000822	0.00139	CcSEcCtD
Imiquimod—Rhinitis—Epirubicin—liver cancer	0.00082	0.00139	CcSEcCtD
Imiquimod—Urinary tract infection—Doxorubicin—liver cancer	0.000819	0.00139	CcSEcCtD
Imiquimod—Conjunctivitis—Doxorubicin—liver cancer	0.000819	0.00139	CcSEcCtD
Imiquimod—Haemorrhage—Epirubicin—liver cancer	0.000818	0.00138	CcSEcCtD
Imiquimod—Pharyngitis—Epirubicin—liver cancer	0.000812	0.00137	CcSEcCtD
Imiquimod—Urinary tract disorder—Epirubicin—liver cancer	0.000808	0.00137	CcSEcCtD
Imiquimod—Connective tissue disorder—Epirubicin—liver cancer	0.000804	0.00136	CcSEcCtD
Imiquimod—Urethral disorder—Epirubicin—liver cancer	0.000802	0.00136	CcSEcCtD
Imiquimod—Hepatobiliary disease—Doxorubicin—liver cancer	0.000797	0.00135	CcSEcCtD
Imiquimod—Sinusitis—Doxorubicin—liver cancer	0.000791	0.00134	CcSEcCtD
Imiquimod—Visual impairment—Epirubicin—liver cancer	0.000788	0.00133	CcSEcCtD
Imiquimod—Erythema multiforme—Epirubicin—liver cancer	0.000773	0.00131	CcSEcCtD
Imiquimod—CYP1A2—Phase II conjugation—GSTA1—liver cancer	0.000768	0.00192	CbGpPWpGaD
Imiquimod—Eye disorder—Epirubicin—liver cancer	0.000764	0.00129	CcSEcCtD
Imiquimod—Tinnitus—Epirubicin—liver cancer	0.000763	0.00129	CcSEcCtD
Imiquimod—CYP1A2—Estrogen Receptor Pathway—STAT3—liver cancer	0.000762	0.00191	CbGpPWpGaD
Imiquimod—Haemoglobin—Doxorubicin—liver cancer	0.000761	0.00129	CcSEcCtD
Imiquimod—CYP1A2—Phase II conjugation—NAT2—liver cancer	0.00076	0.0019	CbGpPWpGaD
Imiquimod—Flushing—Epirubicin—liver cancer	0.000759	0.00128	CcSEcCtD
Imiquimod—Rhinitis—Doxorubicin—liver cancer	0.000759	0.00128	CcSEcCtD
Imiquimod—Haemorrhage—Doxorubicin—liver cancer	0.000757	0.00128	CcSEcCtD
Imiquimod—Pharyngitis—Doxorubicin—liver cancer	0.000751	0.00127	CcSEcCtD
Imiquimod—Urinary tract disorder—Doxorubicin—liver cancer	0.000747	0.00126	CcSEcCtD
Imiquimod—Connective tissue disorder—Doxorubicin—liver cancer	0.000744	0.00126	CcSEcCtD
Imiquimod—Angiopathy—Epirubicin—liver cancer	0.000742	0.00126	CcSEcCtD
Imiquimod—Urethral disorder—Doxorubicin—liver cancer	0.000742	0.00126	CcSEcCtD
Imiquimod—TLR7—Immune System—ADAM17—liver cancer	0.00074	0.00185	CbGpPWpGaD
Imiquimod—Immune system disorder—Epirubicin—liver cancer	0.000739	0.00125	CcSEcCtD
Imiquimod—Mediastinal disorder—Epirubicin—liver cancer	0.000737	0.00125	CcSEcCtD
Imiquimod—Chills—Epirubicin—liver cancer	0.000734	0.00124	CcSEcCtD
Imiquimod—TLR7—Regulation of toll-like receptor signaling pathway—AKT1—liver cancer	0.000732	0.00183	CbGpPWpGaD
Imiquimod—Arrhythmia—Epirubicin—liver cancer	0.000731	0.00124	CcSEcCtD
Imiquimod—Visual impairment—Doxorubicin—liver cancer	0.000729	0.00123	CcSEcCtD
Imiquimod—Alopecia—Epirubicin—liver cancer	0.000723	0.00122	CcSEcCtD
Imiquimod—Mental disorder—Epirubicin—liver cancer	0.000716	0.00121	CcSEcCtD
Imiquimod—Erythema multiforme—Doxorubicin—liver cancer	0.000715	0.00121	CcSEcCtD
Imiquimod—CYP1A2—Arachidonic acid metabolism—GGT1—liver cancer	0.000714	0.00179	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—PIK3CD—liver cancer	0.000713	0.00179	CbGpPWpGaD
Imiquimod—Erythema—Epirubicin—liver cancer	0.000712	0.0012	CcSEcCtD
Imiquimod—Malnutrition—Epirubicin—liver cancer	0.000712	0.0012	CcSEcCtD
Imiquimod—TLR8—Immune System—PRKCE—liver cancer	0.000711	0.00178	CbGpPWpGaD
Imiquimod—Eye disorder—Doxorubicin—liver cancer	0.000707	0.0012	CcSEcCtD
Imiquimod—Tinnitus—Doxorubicin—liver cancer	0.000706	0.00119	CcSEcCtD
Imiquimod—CYP3A4—Biological oxidations—UGDH—liver cancer	0.000702	0.00176	CbGpPWpGaD
Imiquimod—Flushing—Doxorubicin—liver cancer	0.000702	0.00119	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—BCL2L1—liver cancer	0.0007	0.00175	CbGpPWpGaD
Imiquimod—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	0.000696	0.00174	CbGpPWpGaD
Imiquimod—TLR7—Immune System—PSMA4—liver cancer	0.000695	0.00174	CbGpPWpGaD
Imiquimod—TLR7—Immune System—PSMD10—liver cancer	0.000695	0.00174	CbGpPWpGaD
Imiquimod—Back pain—Epirubicin—liver cancer	0.000689	0.00117	CcSEcCtD
Imiquimod—Angiopathy—Doxorubicin—liver cancer	0.000687	0.00116	CcSEcCtD
Imiquimod—Immune system disorder—Doxorubicin—liver cancer	0.000683	0.00116	CcSEcCtD
Imiquimod—Mediastinal disorder—Doxorubicin—liver cancer	0.000682	0.00115	CcSEcCtD
Imiquimod—Chills—Doxorubicin—liver cancer	0.000679	0.00115	CcSEcCtD
Imiquimod—TLR8—Immune System—ABL1—liver cancer	0.000676	0.00169	CbGpPWpGaD
Imiquimod—Arrhythmia—Doxorubicin—liver cancer	0.000676	0.00114	CcSEcCtD
Imiquimod—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2E1—liver cancer	0.000673	0.00168	CbGpPWpGaD
Imiquimod—Alopecia—Doxorubicin—liver cancer	0.000669	0.00113	CcSEcCtD
Imiquimod—CYP1A2—Oxidation by Cytochrome P450—CYP2E1—liver cancer	0.000664	0.00166	CbGpPWpGaD
Imiquimod—Mental disorder—Doxorubicin—liver cancer	0.000663	0.00112	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—MAPK14—liver cancer	0.000663	0.00166	CbGpPWpGaD
Imiquimod—Ill-defined disorder—Epirubicin—liver cancer	0.000661	0.00112	CcSEcCtD
Imiquimod—Erythema—Doxorubicin—liver cancer	0.000659	0.00111	CcSEcCtD
Imiquimod—Malnutrition—Doxorubicin—liver cancer	0.000659	0.00111	CcSEcCtD
Imiquimod—Agitation—Epirubicin—liver cancer	0.000654	0.00111	CcSEcCtD
Imiquimod—CYP3A4—Tryptophan metabolism—CYP2E1—liver cancer	0.000642	0.00161	CbGpPWpGaD
Imiquimod—Malaise—Epirubicin—liver cancer	0.000642	0.00109	CcSEcCtD
Imiquimod—Syncope—Epirubicin—liver cancer	0.000638	0.00108	CcSEcCtD
Imiquimod—Back pain—Doxorubicin—liver cancer	0.000637	0.00108	CcSEcCtD
Imiquimod—TLR8—Innate Immune System—RAF1—liver cancer	0.000636	0.00159	CbGpPWpGaD
Imiquimod—TLR8—Immune System—HGF—liver cancer	0.000636	0.00159	CbGpPWpGaD
Imiquimod—Palpitations—Epirubicin—liver cancer	0.000629	0.00106	CcSEcCtD
Imiquimod—TLR8—Immune System—CSF2—liver cancer	0.000629	0.00158	CbGpPWpGaD
Imiquimod—TLR8—Immune System—CD8A—liver cancer	0.000629	0.00158	CbGpPWpGaD
Imiquimod—Loss of consciousness—Epirubicin—liver cancer	0.000626	0.00106	CcSEcCtD
Imiquimod—Cough—Epirubicin—liver cancer	0.000621	0.00105	CcSEcCtD
Imiquimod—TLR8—Innate Immune System—MTOR—liver cancer	0.000621	0.00156	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—PIK3CB—liver cancer	0.000621	0.00156	CbGpPWpGaD
Imiquimod—Convulsion—Epirubicin—liver cancer	0.000617	0.00104	CcSEcCtD
Imiquimod—Hypertension—Epirubicin—liver cancer	0.000615	0.00104	CcSEcCtD
Imiquimod—Ill-defined disorder—Doxorubicin—liver cancer	0.000611	0.00103	CcSEcCtD
Imiquimod—TLR7—Immune System—IFNA1—liver cancer	0.000609	0.00153	CbGpPWpGaD
Imiquimod—CYP1A2—Phase II conjugation—HPGDS—liver cancer	0.000607	0.00152	CbGpPWpGaD
Imiquimod—Arthralgia—Epirubicin—liver cancer	0.000606	0.00103	CcSEcCtD
Imiquimod—Myalgia—Epirubicin—liver cancer	0.000606	0.00103	CcSEcCtD
Imiquimod—Chest pain—Epirubicin—liver cancer	0.000606	0.00103	CcSEcCtD
Imiquimod—Agitation—Doxorubicin—liver cancer	0.000605	0.00102	CcSEcCtD
Imiquimod—Anxiety—Epirubicin—liver cancer	0.000604	0.00102	CcSEcCtD
Imiquimod—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000602	0.00102	CcSEcCtD
Imiquimod—Discomfort—Epirubicin—liver cancer	0.000599	0.00101	CcSEcCtD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—liver cancer	0.000598	0.0015	CbGpPWpGaD
Imiquimod—CYP1A2—Tryptophan metabolism—CYP1A1—liver cancer	0.000598	0.0015	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—liver cancer	0.000598	0.0015	CbGpPWpGaD
Imiquimod—Malaise—Doxorubicin—liver cancer	0.000594	0.00101	CcSEcCtD
Imiquimod—Dry mouth—Epirubicin—liver cancer	0.000593	0.001	CcSEcCtD
Imiquimod—Syncope—Doxorubicin—liver cancer	0.000591	0.001	CcSEcCtD
Imiquimod—TLR8—Innate Immune System—CDKN1B—liver cancer	0.000583	0.00146	CbGpPWpGaD
Imiquimod—Palpitations—Doxorubicin—liver cancer	0.000582	0.000985	CcSEcCtD
Imiquimod—Oedema—Epirubicin—liver cancer	0.000581	0.000983	CcSEcCtD
Imiquimod—Loss of consciousness—Doxorubicin—liver cancer	0.000579	0.00098	CcSEcCtD
Imiquimod—Infection—Epirubicin—liver cancer	0.000577	0.000977	CcSEcCtD
Imiquimod—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.000575	0.00144	CbGpPWpGaD
Imiquimod—Cough—Doxorubicin—liver cancer	0.000575	0.000973	CcSEcCtD
Imiquimod—Shock—Epirubicin—liver cancer	0.000572	0.000967	CcSEcCtD
Imiquimod—Convulsion—Doxorubicin—liver cancer	0.000571	0.000966	CcSEcCtD
Imiquimod—Nervous system disorder—Epirubicin—liver cancer	0.00057	0.000964	CcSEcCtD
Imiquimod—Hypertension—Doxorubicin—liver cancer	0.000569	0.000962	CcSEcCtD
Imiquimod—Tachycardia—Epirubicin—liver cancer	0.000567	0.00096	CcSEcCtD
Imiquimod—Skin disorder—Epirubicin—liver cancer	0.000564	0.000955	CcSEcCtD
Imiquimod—Hyperhidrosis—Epirubicin—liver cancer	0.000562	0.00095	CcSEcCtD
Imiquimod—Myalgia—Doxorubicin—liver cancer	0.000561	0.000949	CcSEcCtD
Imiquimod—Chest pain—Doxorubicin—liver cancer	0.000561	0.000949	CcSEcCtD
Imiquimod—Arthralgia—Doxorubicin—liver cancer	0.000561	0.000949	CcSEcCtD
Imiquimod—CYP1A2—Arachidonic acid metabolism—CYP1A1—liver cancer	0.000559	0.0014	CbGpPWpGaD
Imiquimod—Anxiety—Doxorubicin—liver cancer	0.000559	0.000946	CcSEcCtD
Imiquimod—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000557	0.000942	CcSEcCtD
Imiquimod—TLR8—Innate Immune System—JUN—liver cancer	0.000555	0.00139	CbGpPWpGaD
Imiquimod—Discomfort—Doxorubicin—liver cancer	0.000554	0.000938	CcSEcCtD
Imiquimod—Anorexia—Epirubicin—liver cancer	0.000554	0.000937	CcSEcCtD
Imiquimod—TLR8—Innate Immune System—CTNNB1—liver cancer	0.000551	0.00138	CbGpPWpGaD
Imiquimod—Dry mouth—Doxorubicin—liver cancer	0.000548	0.000928	CcSEcCtD
Imiquimod—CYP1A2—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.000545	0.00137	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—PIK3CD—liver cancer	0.00054	0.00135	CbGpPWpGaD
Imiquimod—TLR7—Immune System—PRKCE—liver cancer	0.000539	0.00135	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—CDKN1A—liver cancer	0.000538	0.00135	CbGpPWpGaD
Imiquimod—TLR8—Immune System—BCL2L1—liver cancer	0.000538	0.00135	CbGpPWpGaD
Imiquimod—Oedema—Doxorubicin—liver cancer	0.000538	0.00091	CcSEcCtD
Imiquimod—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	0.000537	0.00135	CbGpPWpGaD
Imiquimod—Infection—Doxorubicin—liver cancer	0.000534	0.000904	CcSEcCtD
Imiquimod—CYP1A2—Biological oxidations—NR1H4—liver cancer	0.000532	0.00133	CbGpPWpGaD
Imiquimod—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000529	0.000896	CcSEcCtD
Imiquimod—Shock—Doxorubicin—liver cancer	0.000529	0.000895	CcSEcCtD
Imiquimod—Nervous system disorder—Doxorubicin—liver cancer	0.000527	0.000892	CcSEcCtD
Imiquimod—Insomnia—Epirubicin—liver cancer	0.000526	0.000889	CcSEcCtD
Imiquimod—TLR8—Innate Immune System—MAPK8—liver cancer	0.000525	0.00132	CbGpPWpGaD
Imiquimod—Tachycardia—Doxorubicin—liver cancer	0.000525	0.000888	CcSEcCtD
Imiquimod—CYP1A2—Biological oxidations—GSTA3—liver cancer	0.000523	0.00131	CbGpPWpGaD
Imiquimod—Skin disorder—Doxorubicin—liver cancer	0.000522	0.000884	CcSEcCtD
Imiquimod—Paraesthesia—Epirubicin—liver cancer	0.000522	0.000883	CcSEcCtD
Imiquimod—Hyperhidrosis—Doxorubicin—liver cancer	0.00052	0.000879	CcSEcCtD
Imiquimod—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—liver cancer	0.000519	0.0013	CbGpPWpGaD
Imiquimod—Dyspnoea—Epirubicin—liver cancer	0.000518	0.000877	CcSEcCtD
Imiquimod—Somnolence—Epirubicin—liver cancer	0.000517	0.000874	CcSEcCtD
Imiquimod—CYP1A2—Metapathway biotransformation—GSTA3—liver cancer	0.000516	0.00129	CbGpPWpGaD
Imiquimod—TLR7—Immune System—ABL1—liver cancer	0.000513	0.00128	CbGpPWpGaD
Imiquimod—Anorexia—Doxorubicin—liver cancer	0.000512	0.000867	CcSEcCtD
Imiquimod—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—liver cancer	0.000512	0.00128	CbGpPWpGaD
Imiquimod—Dyspepsia—Epirubicin—liver cancer	0.000511	0.000865	CcSEcCtD
Imiquimod—TLR8—Immune System—MAPK14—liver cancer	0.000509	0.00128	CbGpPWpGaD
Imiquimod—Decreased appetite—Epirubicin—liver cancer	0.000505	0.000855	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Epirubicin—liver cancer	0.000502	0.000849	CcSEcCtD
Imiquimod—Fatigue—Epirubicin—liver cancer	0.000501	0.000848	CcSEcCtD
Imiquimod—Pain—Epirubicin—liver cancer	0.000497	0.000841	CcSEcCtD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—liver cancer	0.000495	0.00124	CbGpPWpGaD
Imiquimod—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00049	0.000829	CcSEcCtD
Imiquimod—Insomnia—Doxorubicin—liver cancer	0.000486	0.000823	CcSEcCtD
Imiquimod—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	0.000483	0.00121	CbGpPWpGaD
Imiquimod—Paraesthesia—Doxorubicin—liver cancer	0.000483	0.000817	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—RAF1—liver cancer	0.000482	0.00121	CbGpPWpGaD
Imiquimod—TLR7—Immune System—HGF—liver cancer	0.000482	0.00121	CbGpPWpGaD
Imiquimod—Dyspnoea—Doxorubicin—liver cancer	0.000479	0.000811	CcSEcCtD
Imiquimod—Feeling abnormal—Epirubicin—liver cancer	0.000479	0.00081	CcSEcCtD
Imiquimod—CYP1A2—Biological oxidations—GSTA4—liver cancer	0.000478	0.0012	CbGpPWpGaD
Imiquimod—Somnolence—Doxorubicin—liver cancer	0.000478	0.000809	CcSEcCtD
Imiquimod—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—liver cancer	0.000477	0.00119	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CD8A—liver cancer	0.000477	0.00119	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CSF2—liver cancer	0.000477	0.00119	CbGpPWpGaD
Imiquimod—Gastrointestinal pain—Epirubicin—liver cancer	0.000475	0.000804	CcSEcCtD
Imiquimod—Dyspepsia—Doxorubicin—liver cancer	0.000473	0.000801	CcSEcCtD
Imiquimod—CYP1A2—Metapathway biotransformation—GSTA4—liver cancer	0.000471	0.00118	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—PIK3CB—liver cancer	0.000471	0.00118	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—MTOR—liver cancer	0.000471	0.00118	CbGpPWpGaD
Imiquimod—Decreased appetite—Doxorubicin—liver cancer	0.000467	0.000791	CcSEcCtD
Imiquimod—CYP1A2—Biological oxidations—GSTA2—liver cancer	0.000466	0.00117	CbGpPWpGaD
Imiquimod—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000464	0.000785	CcSEcCtD
Imiquimod—Fatigue—Doxorubicin—liver cancer	0.000464	0.000784	CcSEcCtD
Imiquimod—Urticaria—Epirubicin—liver cancer	0.000462	0.000781	CcSEcCtD
Imiquimod—CYP3A4—Tryptophan metabolism—CYP1A1—liver cancer	0.000461	0.00116	CbGpPWpGaD
Imiquimod—Pain—Doxorubicin—liver cancer	0.00046	0.000778	CcSEcCtD
Imiquimod—Body temperature increased—Epirubicin—liver cancer	0.000459	0.000777	CcSEcCtD
Imiquimod—Abdominal pain—Epirubicin—liver cancer	0.000459	0.000777	CcSEcCtD
Imiquimod—CYP1A2—Phase II conjugation—GGT1—liver cancer	0.000455	0.00114	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—GSTA1—liver cancer	0.000449	0.00113	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—NAT2—liver cancer	0.000444	0.00111	CbGpPWpGaD
Imiquimod—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.000444	0.00111	CbGpPWpGaD
Imiquimod—Feeling abnormal—Doxorubicin—liver cancer	0.000443	0.00075	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—CDKN1B—liver cancer	0.000442	0.00111	CbGpPWpGaD
Imiquimod—Gastrointestinal pain—Doxorubicin—liver cancer	0.00044	0.000744	CcSEcCtD
Imiquimod—CYP1A2—Metapathway biotransformation—NAT2—liver cancer	0.000438	0.0011	CbGpPWpGaD
Imiquimod—TLR8—Immune System—CDH1—liver cancer	0.000435	0.00109	CbGpPWpGaD
Imiquimod—Hypersensitivity—Epirubicin—liver cancer	0.000428	0.000724	CcSEcCtD
Imiquimod—Urticaria—Doxorubicin—liver cancer	0.000427	0.000723	CcSEcCtD
Imiquimod—Abdominal pain—Doxorubicin—liver cancer	0.000425	0.000719	CcSEcCtD
Imiquimod—Body temperature increased—Doxorubicin—liver cancer	0.000425	0.000719	CcSEcCtD
Imiquimod—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.000421	0.00105	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—JUN—liver cancer	0.000421	0.00105	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—CTNNB1—liver cancer	0.000417	0.00105	CbGpPWpGaD
Imiquimod—Asthenia—Epirubicin—liver cancer	0.000417	0.000705	CcSEcCtD
Imiquimod—TLR8—Immune System—PIK3CD—liver cancer	0.000415	0.00104	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—KRAS—liver cancer	0.000412	0.00103	CbGpPWpGaD
Imiquimod—Pruritus—Epirubicin—liver cancer	0.000411	0.000696	CcSEcCtD
Imiquimod—CYP3A4—Biological oxidations—NR1H4—liver cancer	0.00041	0.00103	CbGpPWpGaD
Imiquimod—CYP1A2—Phase II conjugation—GSTP1—liver cancer	0.000408	0.00102	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—CDKN1A—liver cancer	0.000408	0.00102	CbGpPWpGaD
Imiquimod—TLR7—Immune System—BCL2L1—liver cancer	0.000408	0.00102	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—GSTA3—liver cancer	0.000403	0.00101	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—MAPK8—liver cancer	0.000398	0.000997	CbGpPWpGaD
Imiquimod—CYP3A4—Metapathway biotransformation—GSTA3—liver cancer	0.000398	0.000997	CbGpPWpGaD
Imiquimod—Diarrhoea—Epirubicin—liver cancer	0.000398	0.000673	CcSEcCtD
Imiquimod—Hypersensitivity—Doxorubicin—liver cancer	0.000396	0.00067	CcSEcCtD
Imiquimod—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.000392	0.000981	CbGpPWpGaD
Imiquimod—TLR7—Immune System—MAPK14—liver cancer	0.000386	0.000967	CbGpPWpGaD
Imiquimod—Asthenia—Doxorubicin—liver cancer	0.000386	0.000653	CcSEcCtD
Imiquimod—Dizziness—Epirubicin—liver cancer	0.000384	0.00065	CcSEcCtD
Imiquimod—Pruritus—Doxorubicin—liver cancer	0.00038	0.000644	CcSEcCtD
Imiquimod—TLR8—Innate Immune System—PIK3CA—liver cancer	0.000379	0.000949	CbGpPWpGaD
Imiquimod—CYP1A2—Phase II conjugation—GSTM1—liver cancer	0.000375	0.00094	CbGpPWpGaD
Imiquimod—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	0.000373	0.000934	CbGpPWpGaD
Imiquimod—CYP1A2—Metapathway biotransformation—GPX3—liver cancer	0.000373	0.000934	CbGpPWpGaD
Imiquimod—TLR8—Immune System—RAF1—liver cancer	0.000371	0.000928	CbGpPWpGaD
Imiquimod—Vomiting—Epirubicin—liver cancer	0.000369	0.000625	CcSEcCtD
Imiquimod—CYP3A4—Biological oxidations—GSTA4—liver cancer	0.000369	0.000924	CbGpPWpGaD
Imiquimod—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—liver cancer	0.000368	0.000922	CbGpPWpGaD
Imiquimod—Diarrhoea—Doxorubicin—liver cancer	0.000368	0.000622	CcSEcCtD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—liver cancer	0.000367	0.00092	CbGpPWpGaD
Imiquimod—Rash—Epirubicin—liver cancer	0.000366	0.00062	CcSEcCtD
Imiquimod—Dermatitis—Epirubicin—liver cancer	0.000366	0.000619	CcSEcCtD
Imiquimod—Headache—Epirubicin—liver cancer	0.000364	0.000616	CcSEcCtD
Imiquimod—CYP3A4—Metapathway biotransformation—GSTA4—liver cancer	0.000364	0.000912	CbGpPWpGaD
Imiquimod—TLR8—Immune System—MTOR—liver cancer	0.000362	0.000906	CbGpPWpGaD
Imiquimod—TLR8—Immune System—PIK3CB—liver cancer	0.000362	0.000906	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—GSTA2—liver cancer	0.00036	0.000901	CbGpPWpGaD
Imiquimod—Dizziness—Doxorubicin—liver cancer	0.000356	0.000602	CcSEcCtD
Imiquimod—CYP1A2—Biological oxidations—HPGDS—liver cancer	0.000355	0.00089	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—HRAS—liver cancer	0.00035	0.000878	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—GSTA1—liver cancer	0.000347	0.000869	CbGpPWpGaD
Imiquimod—Nausea—Epirubicin—liver cancer	0.000345	0.000584	CcSEcCtD
Imiquimod—CYP3A4—Biological oxidations—NAT2—liver cancer	0.000343	0.000859	CbGpPWpGaD
Imiquimod—Vomiting—Doxorubicin—liver cancer	0.000342	0.000578	CcSEcCtD
Imiquimod—TLR8—Immune System—CDKN1B—liver cancer	0.00034	0.000851	CbGpPWpGaD
Imiquimod—Rash—Doxorubicin—liver cancer	0.000339	0.000574	CcSEcCtD
Imiquimod—Dermatitis—Doxorubicin—liver cancer	0.000339	0.000573	CcSEcCtD
Imiquimod—CYP3A4—Metapathway biotransformation—NAT2—liver cancer	0.000338	0.000847	CbGpPWpGaD
Imiquimod—Headache—Doxorubicin—liver cancer	0.000337	0.00057	CcSEcCtD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—liver cancer	0.000337	0.000843	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—liver cancer	0.000337	0.000843	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—IL6—liver cancer	0.000335	0.00084	CbGpPWpGaD
Imiquimod—TLR8—Immune System—IL2—liver cancer	0.000332	0.000832	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—liver cancer	0.000329	0.000825	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CDH1—liver cancer	0.000329	0.000825	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—EPT1—liver cancer	0.000329	0.000823	CbGpPWpGaD
Imiquimod—TLR8—Immune System—JUN—liver cancer	0.000323	0.00081	CbGpPWpGaD
Imiquimod—TLR8—Immune System—CTNNB1—liver cancer	0.000321	0.000804	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—liver cancer	0.00032	0.000803	CbGpPWpGaD
Imiquimod—Nausea—Doxorubicin—liver cancer	0.000319	0.00054	CcSEcCtD
Imiquimod—TLR7—Immune System—PIK3CD—liver cancer	0.000315	0.000788	CbGpPWpGaD
Imiquimod—TLR8—Immune System—CDKN1A—liver cancer	0.000313	0.000785	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—KRAS—liver cancer	0.000312	0.000783	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—liver cancer	0.000311	0.000778	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—AKT1—liver cancer	0.000309	0.000775	CbGpPWpGaD
Imiquimod—TLR8—Immune System—MAPK8—liver cancer	0.000306	0.000766	CbGpPWpGaD
Imiquimod—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.000302	0.000757	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—CYP2E1—liver cancer	0.00029	0.000726	CbGpPWpGaD
Imiquimod—CYP3A4—Metapathway biotransformation—GPX3—liver cancer	0.000288	0.000721	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—PIK3CA—liver cancer	0.000287	0.000719	CbGpPWpGaD
Imiquimod—CYP1A2—Metapathway biotransformation—CYP2E1—liver cancer	0.000286	0.000716	CbGpPWpGaD
Imiquimod—TLR7—Immune System—RAF1—liver cancer	0.000281	0.000704	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—liver cancer	0.00028	0.000701	CbGpPWpGaD
Imiquimod—TLR8—Immune System—STAT3—liver cancer	0.00028	0.000701	CbGpPWpGaD
Imiquimod—TLR7—Immune System—MTOR—liver cancer	0.000274	0.000687	CbGpPWpGaD
Imiquimod—TLR7—Immune System—PIK3CB—liver cancer	0.000274	0.000687	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—HPGDS—liver cancer	0.000274	0.000687	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—GGT1—liver cancer	0.000266	0.000666	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—HRAS—liver cancer	0.000266	0.000665	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—MYC—liver cancer	0.000258	0.000645	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CDKN1B—liver cancer	0.000257	0.000645	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—liver cancer	0.000257	0.000644	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—IL6—liver cancer	0.000254	0.000637	CbGpPWpGaD
Imiquimod—TLR7—Immune System—IL2—liver cancer	0.000252	0.000631	CbGpPWpGaD
Imiquimod—TLR7—Immune System—JUN—liver cancer	0.000245	0.000614	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CTNNB1—liver cancer	0.000243	0.000609	CbGpPWpGaD
Imiquimod—TLR8—Immune System—KRAS—liver cancer	0.00024	0.000601	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—liver cancer	0.00024	0.000601	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—TNF—liver cancer	0.00024	0.000601	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—GSTP1—liver cancer	0.000239	0.000598	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—liver cancer	0.000238	0.000596	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CDKN1A—liver cancer	0.000237	0.000595	CbGpPWpGaD
Imiquimod—CYP1A2—Metapathway biotransformation—GSTP1—liver cancer	0.000236	0.00059	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—AKT1—liver cancer	0.000234	0.000587	CbGpPWpGaD
Imiquimod—TLR7—Immune System—MAPK8—liver cancer	0.000232	0.000581	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—CYP2E1—liver cancer	0.000224	0.00056	CbGpPWpGaD
Imiquimod—TLR8—Immune System—PIK3CA—liver cancer	0.000221	0.000553	CbGpPWpGaD
Imiquimod—CYP3A4—Metapathway biotransformation—CYP2E1—liver cancer	0.00022	0.000552	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—GSTM1—liver cancer	0.00022	0.00055	CbGpPWpGaD
Imiquimod—CYP1A2—Metapathway biotransformation—GSTM1—liver cancer	0.000216	0.000542	CbGpPWpGaD
Imiquimod—TLR7—Immune System—STAT3—liver cancer	0.000212	0.000531	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	0.000212	0.00053	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—CYP1A1—liver cancer	0.000208	0.000521	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—GGT1—liver cancer	0.000205	0.000514	CbGpPWpGaD
Imiquimod—CYP1A2—Metapathway biotransformation—CYP1A1—liver cancer	0.000205	0.000514	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	0.000204	0.000511	CbGpPWpGaD
Imiquimod—TLR8—Immune System—HRAS—liver cancer	0.000204	0.000511	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—liver cancer	0.000202	0.000507	CbGpPWpGaD
Imiquimod—TLR8—Immune System—IL6—liver cancer	0.000195	0.000489	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—GSTP1—liver cancer	0.000184	0.000462	CbGpPWpGaD
Imiquimod—TLR7—Immune System—KRAS—liver cancer	0.000182	0.000456	CbGpPWpGaD
Imiquimod—CYP3A4—Metapathway biotransformation—GSTP1—liver cancer	0.000182	0.000455	CbGpPWpGaD
Imiquimod—TLR8—Immune System—AKT1—liver cancer	0.00018	0.000451	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—GSTM1—liver cancer	0.000169	0.000424	CbGpPWpGaD
Imiquimod—TLR7—Immune System—PIK3CA—liver cancer	0.000167	0.000419	CbGpPWpGaD
Imiquimod—CYP3A4—Metapathway biotransformation—GSTM1—liver cancer	0.000167	0.000419	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—CYP1A1—liver cancer	0.000161	0.000402	CbGpPWpGaD
Imiquimod—CYP3A4—Metapathway biotransformation—CYP1A1—liver cancer	0.000158	0.000397	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	0.000156	0.000391	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—UGDH—liver cancer	0.000156	0.00039	CbGpPWpGaD
Imiquimod—TLR7—Immune System—HRAS—liver cancer	0.000155	0.000387	CbGpPWpGaD
Imiquimod—TLR7—Immune System—IL6—liver cancer	0.000148	0.000371	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—EPT1—liver cancer	0.000146	0.000367	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—TAT—liver cancer	0.000139	0.000348	CbGpPWpGaD
Imiquimod—TLR7—Immune System—AKT1—liver cancer	0.000137	0.000342	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	0.000136	0.000342	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—UGDH—liver cancer	0.00012	0.000301	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—EPT1—liver cancer	0.000113	0.000283	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—TAT—liver cancer	0.000107	0.000268	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—liver cancer	0.000102	0.000256	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CPT1B—liver cancer	9.43e-05	0.000236	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GLUL—liver cancer	9.43e-05	0.000236	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—NR1H4—liver cancer	9.09e-05	0.000228	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GSTA3—liver cancer	8.94e-05	0.000224	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GSTA4—liver cancer	8.18e-05	0.000205	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	7.99e-05	0.0002	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GSTA2—liver cancer	7.97e-05	0.0002	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GSTA1—liver cancer	7.69e-05	0.000193	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—NAT2—liver cancer	7.6e-05	0.00019	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—liver cancer	7.31e-05	0.000183	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ALDOB—liver cancer	7.29e-05	0.000183	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CPT1B—liver cancer	7.28e-05	0.000182	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GLUL—liver cancer	7.28e-05	0.000182	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—NR1H4—liver cancer	7.02e-05	0.000176	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CRABP1—liver cancer	6.95e-05	0.000174	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GSTA3—liver cancer	6.9e-05	0.000173	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GSTA4—liver cancer	6.31e-05	0.000158	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	6.26e-05	0.000157	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GSTA2—liver cancer	6.15e-05	0.000154	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—HPGDS—liver cancer	6.08e-05	0.000152	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	6.04e-05	0.000151	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GSTA1—liver cancer	5.93e-05	0.000149	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—NAT2—liver cancer	5.87e-05	0.000147	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ALDOB—liver cancer	5.62e-05	0.000141	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	5.5e-05	0.000138	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—ALB—liver cancer	5.43e-05	0.000136	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PSMD10—liver cancer	5.42e-05	0.000136	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PSMA4—liver cancer	5.42e-05	0.000136	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CRABP1—liver cancer	5.36e-05	0.000134	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GOT2—liver cancer	5.27e-05	0.000132	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CYP2E1—liver cancer	4.95e-05	0.000124	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	4.8e-05	0.00012	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—HPGDS—liver cancer	4.69e-05	0.000117	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CYCS—liver cancer	4.63e-05	0.000116	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GGT1—liver cancer	4.55e-05	0.000114	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GOT1—liver cancer	4.55e-05	0.000114	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PSMD10—liver cancer	4.18e-05	0.000105	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PSMA4—liver cancer	4.18e-05	0.000105	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GSTP1—liver cancer	4.08e-05	0.000102	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GOT2—liver cancer	4.07e-05	0.000102	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—HMOX1—liver cancer	4.03e-05	0.000101	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CYP2E1—liver cancer	3.82e-05	9.58e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GSTM1—liver cancer	3.75e-05	9.4e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CYCS—liver cancer	3.58e-05	8.96e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CYP1A1—liver cancer	3.56e-05	8.91e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GGT1—liver cancer	3.51e-05	8.79e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GOT1—liver cancer	3.51e-05	8.79e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—MTHFR—liver cancer	3.32e-05	8.31e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PPARA—liver cancer	3.25e-05	8.15e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GSTP1—liver cancer	3.15e-05	7.9e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—HMOX1—liver cancer	3.11e-05	7.79e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.92e-05	7.32e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GSTM1—liver cancer	2.9e-05	7.26e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PIK3CG—liver cancer	2.79e-05	6.98e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CYP1A1—liver cancer	2.75e-05	6.88e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PPARG—liver cancer	2.69e-05	6.74e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—MTHFR—liver cancer	2.56e-05	6.41e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PPARA—liver cancer	2.51e-05	6.29e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PIK3CD—liver cancer	2.45e-05	6.14e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ALB—liver cancer	2.42e-05	6.06e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PIK3CG—liver cancer	2.15e-05	5.39e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PIK3CB—liver cancer	2.14e-05	5.35e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PPARG—liver cancer	2.08e-05	5.2e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PIK3CD—liver cancer	1.89e-05	4.74e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ALB—liver cancer	1.87e-05	4.68e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PIK3CB—liver cancer	1.65e-05	4.13e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PIK3CA—liver cancer	1.3e-05	3.26e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—AKT1—liver cancer	1.06e-05	2.66e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PIK3CA—liver cancer	1e-05	2.52e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—AKT1—liver cancer	8.21e-06	2.06e-05	CbGpPWpGaD
